Literature DB >> 21063865

Esophageal disease in progressive systemic sclerosis.

Ellen C Ebert1.   

Abstract

OPINION STATEMENT: Progressive systemic sclerosis (PSS) or scleroderma is characterized by fibrosis of the skin and visceral organs. Gastrointestinal disease occurs in up to 90% of patients, with the esophagus being the most commonly affected organ. Heartburn, dysphagia, and regurgitation occur in most patients. Esophageal manometry aids in diagnosing PSS. Endoscopy rules out complications, such as Barrett's esophagus, Candida esophagitis, and cancer. Lifestyle modifications should be implemented, including avoidance of alcohol, nicotine, and NSAIDs. Proton pump inhibitor therapy should be instituted, although it is unclear whether the dose should be adjusted according to symptoms or to 24-hour pH monitoring. Prokinetic agents are useful in the early stages of PSS when gastrointestinal musculature is still intact. Metoclopramide improves reflux, lower esophageal sphincter pressure, and gastric emptying but has an inconsistent effect on esophageal peristalsis. A decision on when to perform antireflux surgery, if at all, is controversial. Esophageal disease in PSS is a common and difficult-to-treat problem.

Entities:  

Year:  2008        PMID: 21063865     DOI: 10.1007/s11938-008-0008-8

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  47 in total

1.  Radionuclide esophageal transit studies in progressive systemic sclerosis: an analysis of longitudinal data.

Authors:  M Baron; A Arzoumanian
Journal:  J Rheumatol       Date:  1991-12       Impact factor: 4.666

Review 2.  Esophageal motor dysfunction in systemic diseases.

Authors:  A K Mukhopadhyay; D Y Graham
Journal:  Arch Intern Med       Date:  1976-05

3.  Prolonged clearance is the primary abnormal reflux parameter in patients with progressive systemic sclerosis and esophagitis.

Authors:  J R Murphy; P McNally; P Peller; S S Shay
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

4.  Gastroesophageal reflux in esophageal scleroderma: diagnosis and implications.

Authors:  M B Orringer; L Dabich; C J Zarafonetis; H Sloan
Journal:  Ann Thorac Surg       Date:  1976-08       Impact factor: 4.330

5.  Esophageal manometry and pH-probe monitoring in the evaluation of gastroesophageal reflux in patients with progressive systemic sclerosis.

Authors:  P Stentoft; L Hendel; S Aggestrup
Journal:  Scand J Gastroenterol       Date:  1987-05       Impact factor: 2.423

6.  Intestinal perforation. A common complication of scleroderma.

Authors:  E C Ebert; F M Ruggiero; J R Seibold
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

7.  Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS.

Authors:  M Ramirez-Mata; G Ibañez; D Alarcon-Segovia
Journal:  Arthritis Rheum       Date:  1977 Jan-Feb

8.  Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis.

Authors:  A Akesson; T Gustafson; F Wollheim; J Brismar
Journal:  Scand J Rheumatol       Date:  1987       Impact factor: 3.641

Review 9.  Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

Authors:  H Sallam; T A McNearney; J D Z Chen
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

10.  Endoluminal ultrasonography of the distal esophagus in systemic sclerosis.

Authors:  L S Miller; J B Liu; P J Klenn; M P Holahan; J Varga; R I Feld; M Troshinsky; S A Jimenez; D O Castell; B B Goldberg
Journal:  Gastroenterology       Date:  1993-07       Impact factor: 22.682

View more
  3 in total

1.  Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.

Authors:  Serena Vettori; Salvatore Tolone; Domenico Capocotta; Rossella Chieffo; Veronica Giacco; Gabriele Valentini; Ludovico Docimo
Journal:  Clin Rheumatol       Date:  2018-02-13       Impact factor: 2.980

Review 2.  Esophageal Dysfunction in Systemic Sclerosis: An Update.

Authors:  Bo Li; Junqing Yan; Jincheng Pu; Jianping Tang; Shuchang Xu; Xuan Wang
Journal:  Rheumatol Ther       Date:  2021-10-09

3.  Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures.

Authors:  Jaclyn N Taroni; Viktor Martyanov; Chiang-Ching Huang; J Matthew Mahoney; Ikuo Hirano; Brandon Shetuni; Guang-Yu Yang; Darren Brenner; Barbara Jung; Tammara A Wood; Swati Bhattacharyya; Orit Almagor; Jungwha Lee; Arlene Sirajuddin; John Varga; Rowland W Chang; Michael L Whitfield; Monique Hinchcliff
Journal:  Arthritis Res Ther       Date:  2015-07-29       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.